Immune · Peptide
LL-37
Also known as Cathelicidin
The body's own antimicrobial peptide, studied for infection and wound healing.
Status as of 2026-07 · reclassification ≠ FDA approval · educational only, not medical advice.
The signal it sends
Disrupts microbial membranes and modulates immune/wound-repair signaling.
Benefits & effects studied
- Antimicrobial research
- Wound-healing interest
Research state
Pre-clinical/early; not approved as a therapy.
Dosing & pharmacokinetics
Investigational. Half-life: Short.
Dosing information is educational only. LL-37 decisions belong with a licensed clinician — Jevity does not recommend or supply dosing.
History & discovery
First described 1995 by Not well documented (independently identified in 1995 by three research groups) Origin: Independently identified in 1995 by three groups from myeloid bone-marrow cDNA and neutrophils; first called FALL-39, then renamed LL-37 once the mature peptide was found to be 37 residues beginning with two leucines. It is the only human cathelicidin..
Molecular structure
A 37-amino-acid antimicrobial peptide (starting with Leu-Leu) cleaved from the C-terminus of the hCAP18 protein encoded by the CAMP gene.
Frequently asked questions
Is LL-37 FDA-approved?
Not FDA-approved — preclinical On Jevity's evidence scale, LL-37 is graded "Animal data only". Reclassification for compounding is not the same as FDA approval.
What is LL-37 used for?
The body's own antimicrobial peptide, studied for infection and wound healing. Disrupts microbial membranes and modulates immune/wound-repair signaling. Studied effects include: Antimicrobial research; Wound-healing interest. This is educational information, not a recommendation to use it.
Is LL-37 legal in the UAE?
UAE / DHA status: Prescription-only via a DHA-licensed clinic
Is LL-37 banned in sport?
WADA status: Verify on current WADA list
What is LL-37's Jevity Score?
LL-37 has a Jevity Score of 25/100 — a proprietary composite of evidence strength (2/10), regulatory clarity (3/10) and supply verifiability (3/10). It reflects how established and legitimate the compound is, not a recommendation.
LL-37 is prescription-only or research-only. A licensed clinician must evaluate whether it's appropriate for you.
Book a consult →Related immune peptides
Educational information only — not medical advice, a diagnosis, or a recommendation to use any substance or therapy. Regulatory status changes; verify current rules and any personal decision with a licensed clinician. Jevity is operated by Upcapital Global FZCO, Dubai, UAE.